Healthcare [ 6/11 ] | Biotechnology [ 76/148 ]
GB | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 9, 23 | 0.21 Increased by +175.00% | 0.17 Increased by +23.53% |
| May 12, 23 | 0.01 Increased by +103.33% | -0.19 Increased by +105.26% |
| Mar 6, 23 | -0.18 Increased by +25.00% | -0.25 Increased by +28.00% |
| Nov 8, 22 | -0.24 Increased by +20.00% | -0.24 |
| Aug 4, 22 | -0.28 Decreased by -16.67% | -0.25 Decreased by -12.00% |
| May 9, 22 | -0.30 Decreased by -25.00% | -0.22 Decreased by -36.36% |
| Mar 14, 22 | -0.24 Increased by 0.00% | 0.14 Decreased by -271.43% |
| Nov 4, 21 | -0.30 Decreased by -25.00% | -0.26 Decreased by -15.38% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 5.13 M Decreased by -7.37% | -21.39 M Increased by +51.96% | Decreased by -416.94% Increased by +48.14% |
| Mar 31, 23 | 47.60 M Increased by +1.23 K% | 1.04 M Increased by +102.06% | Increased by +2.18% Increased by +100.15% |
| Dec 31, 22 | 11.03 M Increased by +678.26% | -29.25 M Increased by +24.73% | Decreased by -265.23% Increased by +90.33% |
| Sep 30, 22 | 7.01 M Increased by +482.46% | -41.42 M Increased by +2.31% | Decreased by -591.14% Increased by +83.23% |
| Jun 30, 22 | 5.54 M Increased by +78.93% | -44.52 M Decreased by -13.96% | Decreased by -803.90% Increased by +36.31% |
| Mar 31, 22 | 3.58 M Increased by +723.73% | -50.27 M Decreased by -33.11% | Decreased by -1.41 K% Increased by +83.84% |
| Dec 31, 21 | 1.42 M Decreased by -5.66% | -38.86 M Decreased by -6.13% | Decreased by -2.74 K% Decreased by -12.50% |
| Sep 30, 21 | 1.20 M Increased by +0.84% | -42.40 M Decreased by -19.67% | Decreased by -3.52 K% Decreased by -18.67% |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.